2 Mar

Major biosimilar patent issues are coming to the boil in the US – here’s what you need to know

Biologic and biosimilar patent strategies are evolving quickly, as are interpretations of the BPCIA. Here are six important developments to watch out for in the coming months and years

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth